Cutting edge: Fas ligand (CD178) cytoplasmic tail is a positive regulator of Fas ligand-mediated

被引:10
|
作者
Jodo, S
Pidiyar, VJ
Xiao, S
Furusaki, A
Sharma, R
Koike, T
Ju, ST [1 ]
机构
[1] Univ Virginia, Dept Internal Med, Div Rheumatol & Immunol, Charlottesville, VA 22908 USA
[2] Hokkaido Univ, Grad Sch Med, Dept Med 2, Sapporo, Hokkaido, Japan
来源
JOURNAL OF IMMUNOLOGY | 2005年 / 174卷 / 08期
关键词
D O I
10.4049/jimmunol.174.8.4470
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The cytotoxic function of CD178 (Tas ligand (FasL)) is critical to the maintenance of peripheral tolerance and immune-mediated tissue pathology. The active site of FasL resides at the FasL extracellular region (FasL(Ext)) and it functions through binding/cross-linking Fas receptor on target cells. In this study, we report that FasL(Ext)-mediated cytotoxicity is regulated by the FasL cytoplasmic tail (Fas(LCyt)). Deleting the N-terminal 2-70 aa (Delta 70) or N-terminal 2-33 aa (Delta 33) reduced the cytotoxic strength as much as 30- to 100-fold. By contrast, change in the cytotoxic strength was not observed with FasL deleted of the proline-rich domains (45-74 aa, Delta PRD) in the FasL(Cyt) Our study identifies a no velfunction of FasL(Cyt) and demonstrates that FasL(Cyt), a sequence unique to FasL, is critically required for the optimal expression of FasL(Ext)-mediated cytotoxicity.
引用
收藏
页码:4470 / 4474
页数:5
相关论文
共 50 条
  • [1] Novel negative regulator of expression in Fas ligand (CD178) cytoplasmic tail: Evidence for translational regulation and against Fas ligand retention in secretory lysosomes
    Xiao, S
    Deshmukh, US
    Jodo, S
    Koike, T
    Sharma, R
    Furusaki, A
    Sung, SSJ
    Ju, ST
    JOURNAL OF IMMUNOLOGY, 2004, 173 (08): : 5095 - 5102
  • [2] Cutting edge: Two distinct motifs within the Fas ligand tail regulate Fas ligand-mediated costimulation
    Sun, Mingyi
    Lee, Shinhee
    Karray, Saoussen
    Levi-Strauss, Matthieu
    Ames, Kristina T.
    Fink, Pamela J.
    JOURNAL OF IMMUNOLOGY, 2007, 179 (09): : 5639 - 5643
  • [3] Differentiation of promyelocytic leukaemia: alterations in Fas (CD95/Apo-1) and Fas Ligand (CD178) expression
    Salih, HR
    Starling, GC
    Brandl, SF
    Pelka-Fleischer, R
    Haferlach, T
    Hiddemann, W
    Kiener, PA
    Nuessler, V
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (01) : 76 - 85
  • [4] Fas/Fas ligand-mediated apoptosis of murine Langerhans cells
    Kawamura, T
    Azuma, M
    Kayagaki, N
    Shimada, S
    Yagita, H
    Okumura, K
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2000, 22 (02) : 96 - 101
  • [5] Fas/Fas ligand-mediated apoptosis as a mechanism of immune privilege
    Ferguson, TA
    Griffith, TS
    FASEB JOURNAL, 1996, 10 (06): : 1588 - 1588
  • [6] Role of Fas/Fas ligand-mediated apoptosis in murine contact hypersensitivity
    Xu, BH
    Bulfone-Paus, S
    Aoyama, K
    Yu, S
    Huang, PX
    Morimoto, K
    Matsushita, T
    Takeuchi, T
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2003, 3 (07) : 927 - 938
  • [7] FAS ligand-mediated liver disease in mice
    Bobé, P
    Bonardelle, D
    Grandjon, D
    Godeau, F
    Joulin, V
    Tricottet, V
    Reynès, M
    Kiger, N
    10TH INTERNATIONAL CONGRESS ON IMMUNOLOGY, VOLS 1 AND 2, 1998, : 1065 - 1071
  • [8] Fas and Fas ligand-mediated apoptosis and its role in autoimmune diabetes
    Signore, A
    Annovazzi, A
    Gradini, R
    Liddi, R
    Ruberti, G
    DIABETES-METABOLISM REVIEWS, 1998, 14 (03): : 197 - 206
  • [9] Selective activation of Fas/Fas ligand-mediated cytotoxicity by a self peptide
    Brossart, P
    Bevan, MJ
    JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (06): : 2449 - 2458
  • [10] Alterations in Fas (CD 95/Apo-1) and Fas ligand (CD178) expression in acute promyelocytic leukemia during treatment with ATRA
    Salih, HR
    Kiener, PA
    LEUKEMIA & LYMPHOMA, 2004, 45 (01) : 55 - 59